A recent study indicates that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end traditional diet and exercise regimens.
Research printed in a prominent health publication points out that while obese individuals can lose substantial amounts of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month after stopping.
"People using these medications need to be aware of the potential of quick weight regain when the medication is stopped," stated expert Dr. Susan Jebb.
This pace of recovery implies a return to original mass within about 18 months.
Analyzing Treatments
The analysis, which examined dozens of studies involving thousands of patients, compared the effects of these new drugs with conventional dieting.
Scientists note that individuals who lose weight through dieting typically have a more gradual weight regain—approximately 0.1 kg a month—once they finish.
Explaining the Rapid Rebound
Nutrition scientists propose the mode of action of the drugs is key to understanding the amplified regain.
The injections imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations far above than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement leads to hunger is unsuppressed, making binge eating far more likely."
A Chronic Condition?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians argue that, due to the significant potential of weight regain, the treatment might need to be long-term.
This view is reinforced by pharmaceutical companies, who note that the results "highlight the long-term nature of obesity," comparing it to managing conditions like diabetes.
User Testimonies
Users who have stopped the jabs explain a intense return of cravings.
"It felt as if something flipping and you're instantly starving," said one woman.
This challenge is compounded if users have not developed lasting dietary or behavioural modifications during therapy.
Significant Adoption
Figures indicate that millions of adults in the UK have tried these injections in the past year, with interest continuing to grow.
- Use is more common among women compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
Ultimately, researchers emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone solution and maintained weight loss relies on integrated behavioural management.
